Predictors and outcomes in breast cancer patients who did or did not pursue fertility preservation

ConclusionsFP is safe and effective in breast cancer patients, regardless of receptor status;E2 elevations and the 2-week delay in treatment start are unlikely to be clinically significant. These findings are unique in that our institution does not use concomitant letrozole during stimulation to minimizeE2 elevations in breast cancer patients.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research